Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 58, Issue -, Pages 3S-9SPublisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.116.186502
Keywords
PRRT; neuroendocrine; somatostatin; PSMA; peptide
Ask authors/readers for more resources
In nuclear medicine, the term theranostics describes the combination of therapy and diagnostic imaging. In practice, this concept dates back more than 50 years; however, among the most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors. The development of these modalities through the radiolabeling of somatostatin analogs with various radionuclides has led to a revolution in patient management and established a foundation for expansion of the theranostic principle into other oncology indications. This article provides a review of the evolution and development of the theranostic radionuclide approach to the management of neuroendocrine tumors, as described by the inventor of this technique, Eric P. Krenning, in an interview with Rachel Levine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available